Organisation paid for research Program year 2025 Source: CMS Open Payments

Dayton Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$2,009,467

483 payments

Through program year 2025, Dayton Clinical Research is reported as receiving $2,009,467 in research payments, across 483 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $91,462 45
2024 Research $230,299 38
2023 Research $224,314 47
2022 Research $378,760 48
2021 Research $327,089 135
2020 Research $539,246 93
2019 Research $218,297 77

Breakdown

Who paid Research payments · program years 2019–2025
  1. Pfizer Inc. $1,232,673 247 payments
  2. Seqirus USA Inc $311,016 12 payments
  3. Merck Sharp & Dohme Corporation $151,671 80 payments
  4. Novo Nordisk AS $119,317 36 payments
  5. GlaxoSmithKline, LLC. $111,894 72 payments
  6. Novavax Inc $60,617 23 payments
  7. Otsuka Pharmaceutical Development & Commercialization, Inc. $8,457 1 payment
  8. Amgen Inc. $5,735 4 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $4,920 1 payment
  10. Sanofi Pasteur Inc. $2,000 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3 Randomized Observerblinded Study to Evaluate the Efficacy Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Influenza Compared to Licensed Inactivated Influenza Vaccine in Healthy Adults 18 Years of Age Or Older $389,574 35 payments
  2. A Phase 123 Placebocontrolled Randomized Observerblind Dosefinding Study to Evaluate the Safety Tolerability Immunogenicity and Efficacy of Sarscov2 Rna Vaccine Candidates Against Covid19 in Healthy Adults $386,801 48 payments
  3. Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects $202,474 9 payments
  4. A Master Phase 123 Protocol to Investigate the Safety Tolerability and Immunogenicity of Bivalent Bnt162b2 Rna Based Vaccine Candidates in Healthy Children $117,241 24 payments
  5. A Phase 3, Randomized, Observer-Blind, Multicenter, Noninferiority Study to Evaluate Safety and Immunogenicity of a Cell-Based Quadrivalent Subunit Influenza Virus Vaccine QIVc and a United States Licensed Quadrivalent Influenza Virus Vaccine QIV in Healthy Subjects 6 Months Through 47 Months $108,542 3 payments
  6. Nn9536-4376 $99,817 30 payments
  7. A Phase 3 Master Protocol to Evaluate Additional Doses of Bnt162b2 in Healthy Individuals Previously Vaccinated With Bnt162b2 $92,644 26 payments
  8. A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of 2-dose Regimens of 9vHPV and mRNA-1273 SARS-CoV-2 Vaccines Where the First Dose of Each Vaccine Are Given Concomitantly in Boys and Girls 9 to 11 Years of Age $84,504 5 payments
  9. A Phase 23 Protocol to Investigate the Safety Tolerability and Immunogenicity of Bnt162b2 Rnabased Vaccine Candidates for Sarscov2 New Variants in Healthy Individuals $73,784 12 payments
  10. A Phase 2 Randomized Doubleblind Trial to Evaluate the Safety Tolerability and Immunogenicity of A Multivalent Pneumococcal Conjugate Vaccine in Healthy Infants $61,721 23 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record